Key facts
- This page summarizes Vivienne I. Rebel's Form 4 filing for bioAffinity Technologies, Inc. (BIAF).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Feb 2024, 16:21.
Vivienne I. Rebel - 31 Jan 2024 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)
- Reporting relationship
- Chief Sci. & Med. Officer, EVP
- Issuer ticker
- BIAF
- Reported as of
- 31 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2024, 16:21:48 UTC
- Prior SEC filing
- 22 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vivienne Rebel
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vivienne I. Rebel filed Form 4 for bioAffinity Technologies, Inc. (BIAF) on 02 Feb 2024.
Change
- Previous filing in this sequence was filed on 22 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIAF
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +31,847
- Change %
- +221%
- Price
- $0.000000
- Shares after
- 46,228
- Date
- 31 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024.
SEC remarks
Exhibit 24.1 - Power of Attorney (Vivienne Rebel)